Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Algernon Interview

<< Previous

Bullboard Posts

Next >>

Comment by Rockafellowon Dec 03, 2020 11:21pm

154 Views

Post# 32034852

RE:RE:Algernon Interview

Hope for us old guys... ...
... ...
Read up on Eli Lilly drug for covid that mirrors the remedy of agn drug effectively stablelizes lung congestion and offers relief to vital organs as well. Agn may be a little more effective but their drug has promise.
I enjoyed ur rank, right on the mark--- thanxs

<< Previous

Bullboard Posts

Next >>

Canadian psychedelic stock to supply MDMA to Yale